Accuray (ARAY) Competitors

Abbott Laboratories has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Abbott Laboratories has a net margin of 13.90% compared to Accuray's net margin of -10.76%. Abbott Laboratories' return on equity of 17.62% beat Accuray's return on equity.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Abbott Laboratories had 47 more articles in the media than Accuray. MarketBeat recorded 47 mentions for Abbott Laboratories and 0 mentions for Accuray. Abbott Laboratories' average media sentiment score of 0.98 beat Accuray's score of 0.00 indicating that Abbott Laboratories is being referred to more favorably in the media.

Abbott Laboratories has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Accuray has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Abbott Laboratories currently has a consensus price target of $118.42, suggesting a potential upside of 24.32%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 684.62%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than Abbott Laboratories.

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Intuitive Surgical has a net margin of 28.15% compared to Accuray's net margin of -10.76%. Intuitive Surgical's return on equity of 15.98% beat Accuray's return on equity.

Intuitive Surgical has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Intuitive Surgical presently has a consensus target price of $573.42, suggesting a potential upside of 34.60%. Accuray has a consensus target price of $2.00, suggesting a potential upside of 684.62%. Given Accuray's higher possible upside, analysts plainly believe Accuray is more favorable than Intuitive Surgical.

Intuitive Surgical has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Accuray has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

In the previous week, Intuitive Surgical had 34 more articles in the media than Accuray. MarketBeat recorded 34 mentions for Intuitive Surgical and 0 mentions for Accuray. Intuitive Surgical's average media sentiment score of 1.08 beat Accuray's score of 0.00 indicating that Intuitive Surgical is being referred to more favorably in the media.

Stryker has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Accuray has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Stryker presently has a consensus target price of $395.33, suggesting a potential upside of 21.12%. Accuray has a consensus target price of $2.00, suggesting a potential upside of 684.62%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Stryker.

Stryker has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Stryker's return on equity of 23.42% beat Accuray's return on equity.

77.1% of Stryker shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 4.6% of Stryker shares are held by company insiders. Comparatively, 4.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Stryker had 30 more articles in the media than Accuray. MarketBeat recorded 30 mentions for Stryker and 0 mentions for Accuray. Stryker's average media sentiment score of 1.25 beat Accuray's score of 0.00 indicating that Stryker is being referred to more favorably in the media.

Accuray currently has a consensus target price of $2.00, suggesting a potential upside of 684.62%. Medtronic has a consensus target price of $99.00, suggesting a potential upside of 19.18%. Given Accuray's higher probable upside, research analysts clearly believe Accuray is more favorable than Medtronic.

In the previous week, Medtronic had 40 more articles in the media than Accuray. MarketBeat recorded 40 mentions for Medtronic and 0 mentions for Accuray. Medtronic's average media sentiment score of 1.39 beat Accuray's score of 0.00 indicating that Medtronic is being referred to more favorably in the news media.

Medtronic has a net margin of 13.20% compared to Accuray's net margin of -10.76%. Medtronic's return on equity of 14.51% beat Accuray's return on equity.

64.1% of Accuray shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 4.4% of Accuray shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medtronic has higher revenue and earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Accuray has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.